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Background: Synthesis and uptake of pyoverdine, the primary siderophore of the opportunistic pathogen
Pseudomonas aeruginosa, is dependent on two extra-cytoplasmic function (ECF) sigma factors, FpvI and PvdS. FpvI
and PvdS are required for expression of the ferri-pyoverdine receptor gene fpvA and of pyoverdine synthesis genes
respectively. In the absence of pyoverdine the anti-sigma factor FpvR that spans the cytoplasmic membrane inhibits
the activities of both FpvI and PvdS, despite the two sigma factors having low sequence identity.
Results: To investigate the interactions of FpvR with FpvI and PvdS, we first used a tandem affinity purification system to
demonstrate binding of PvdS by the cytoplasmic region of FpvR in P. aeruginosa at physiological levels. The cytoplasmic
region of FpvR bound to and inhibited both FpvI and PvdS when the proteins were co-expressed in Escherichia coli. Each
sigma factor was then subjected to error prone PCR and site-directed mutagenesis to identify mutations that increased
sigma factor activity in the presence of FpvR. In FpvI, the amino acid changes clustered around conserved region four of
the protein and are likely to disrupt interactions with FpvR. Deletion of five amino acids from the C-terminal end of FpvI
also disrupted interactions with FpvR. Mutations in PvdS were present in conserved regions two and four. Most of these
mutations as well as deletion of thirteen amino acids from the C-terminal end of PvdS increased sigma factor activity
independent of whether FpvR was present, suggesting that they increase either the stability of PvdS or its affinity for core
RNA polymerase.
Conclusions: These data show that FpvR binds to PvdS in both P. aeruginosa and E. coli, inhibiting its activity. FpvR also
binds to and inhibits FpvI and binding of FpvI is likely to involve conserved region four of the sigma factor protein.
Keywords: Siderophore, Gene expression, ECF sigma factor, Anti-sigma factor, Pyoverdine, Pseudomonas, Cell surface
signaling, TonB-dependent signaling, Tandem affinity purificationBackground
Pseudomonas aeruginosa is a widespread opportunistic
pathogen recognized for its role in morbidity and mor-
tality in cystic fibrosis and burns patients [1]. Like other
bacteria P. aeruginosa has a requirement to take up iron,
which is an essential co-factor in a number of proteins.
P. aeruginosa achieves this via active uptake of iron-
chelating siderophores, with pyoverdine being the pri-
mary siderophore secreted by this bacterium [2]. Once
pyoverdine has bound iron, the cell-surface receptor
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unless otherwise stated.(reviewed in [3]). Expression of pyoverdine synthesis genes
and the fpvA gene is directed by the alternative sigma fac-
tors PvdS and FpvI respectively [4-7], and PvdS is also re-
quired for maximal expression of two secreted virulence
factors, exotoxin A and PrpL protease [8,9]. In the absence
of pyoverdine the activities of PvdS and FpvI are inhibited
by an anti-sigma factor, FpvR, which spans the cytoplas-
mic membrane [6,10,11]. In a positive feedback loop,
interaction of ferri-pyoverdine with FpvA results in pro-
teolytic degradation of FpvR, a process that requires the
energy-transducing protein TonB as well as interaction
between periplasmic domains of the Fpv proteins [12-15].
The sigma factors are then free to recruit core RNA poly-
merase, facilitating promoter recognition with consequent
up-regulation of the pyoverdine synthesis genes and thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Signal transduction systems of this sort (cell-surface sig-
naling) are widespread in Gram negative bacteria and con-
trol the expression of a large number of genes encoding
ferri-siderophore receptor proteins, in a wide range of spe-
cies [11,16,17]. However the ferri-pyoverdine system is the
only cell-surface signaling pathway known in which a sin-
gle anti-sigma factor (FpvR) inhibits two different sigma
factors (PvdS and FpvI). In some cell-surface signaling
pathways, such as the Fec (ferric citrate) pathway in
Escherichia coli [18] and the Fox (desferrioxamine) and
Fiu (ferrichrome) pathways in P. aeruginosa [19] the anti-
sigma factors are also required for sigma factor function
and so are considered to be sigma factor regulators. How-
ever, there is no evidence that FpvR is required for activity
of PvdS or FpvI.
FpvI and PvdS belong to the class IV or extra-
cytoplasmic function (ECF) sigma factors, alternative
sigma factors that control a wide range of functions in
bacteria and are the largest and most diverse group of
sigma factors known (reviewed in [20,21]). Class IV
sigma factors are relatively small and share only two of
the four conserved functional regions present in other
sigma factors, region two and region four, these being
connected by a flexible non-conserved linker. Region
two plays a specific role in −10 promoter recognition
and in DNA melting, and region four recognizes the −35
promoter region [20]. In a previous study, alanine scan-
ning mutagenesis was used to elicit more detail on the
functions of these regions in PvdS [22]. Mutations in re-
gion 2.1 and 2.2 reduced binding to core RNA polymer-
ase and mutations in regions 2.3, 2.4 and 4.2 impaired
DNA binding without affecting binding to core RNA
polymerase. It is very likely that the corresponding re-
gions in FpvI have equivalent functions.
Binding of sigma factors by anti-sigma factor proteins
provides an effective mechanism of post-translational con-
trol of protein activity in cell-surface signaling and many
other bacterial systems. However, there are very few cases
in which sigma/anti-sigma factor interactions have been
characterized at the molecular level and none of these
closely parallel the FpvR/FpvI/PvdS system. One well-
studied example is the stress response sigma factor σE in
complex with the N-terminal (residues 1–66) region of its
anti-sigma factor RseA from E. coli [23]. The region
RseAN1–66 slots between regions two and four of σ
E, mak-
ing extensive interactions that sterically prevent σE from
recruiting core RNA polymerase. The cytoplasmic domain
of the anti-sigma factor ChrR from Rhodobacter sphaer-
oides has a similar structure to RseAN1–66 [24]. This obser-
vation in combination with bioinformatic analysis has led
to the proposal that there is a common structure for the
cytoplasmic domain of class IV anti-sigma factors [24], des-
pite low sequence identity. However, there is considerablevariability amongst ECF sigma factors for the regions bound
by the cognate anti-sigma factor, which can be both region
two and four [23-25], region two alone [26] or region four
alone [27].
Although both are inhibited by FpvR, FpvI and PvdS
have low sequence identity with each other (34.7%) [6].
Previously, bacterial 2-hybrid analysis demonstrated an
interaction between FpvI and FpvR, and PvdS and FpvR,
when each pair was expressed in E. coli [28]. It was also
shown that the cytoplasmic N-terminal 67 amino acids of
FpvR comprised the minimum region required for inter-
action with PvdS and FpvI [28]. Mutations were identified
in fpvI that interfered with the interaction of FpvR and
FpvI although the effects of most of these mutations were
attributed to reduced amounts of FpvI protein, with only
one mutation specifically affecting binding of FpvI by
FpvR. The effect of mutations in PvdS on interactions with
FpvR was not investigated.
The overall aim of the research described here was to
investigate the interactions of FpvR with PvdS and FpvI
in vivo, and to identify amino acid residues in each of
the sigma factors that contribute to those interactions.
Results
Co-purification of FpvR and PvdS from P. aeruginosa
We validated binding of PvdS by FpvR in P. aeruginosa by
purifying the cytoplasmic portion of FpvR and determin-
ing whether PvdS was co-purified. P. aeruginosa (PAO1)
was engineered to express the cytoplasmic portion and
predicted sigma factor inhibitory region of FpvR (residues
1–89) [6,28] fused to a C-terminal tandem affinity pu-
rification (TAP) tag [29]. The FpvR1–89 -TAP fusion,
expressed from the fpvR promoter, was either integrated
into the bacterial chromosome using mini-CTX or was
expressed from plasmid pUCP23. Chromosomal integra-
tion was used to demonstrate that FpvR1–89 and PvdS
interact when expressed in physiological amounts. Higher
plasmid-based expression was expected to titrate out any
regulatory factors that may have limited FpvR1–89 expres-
sion, ensuring sufficient FpvR1–89 was present for visual-
isation and co-purification with PvdS. As expected,
expression of FpvR from the chromosomally-integrated
construct was repressed by the presence of iron in the
King’s B medium (Additional file 1: Figure S1). FpvR1–89
fused to calmodulin binding protein (CBP) was purified
using the TAP protocol. The purification resulted in a
15 kDa protein, the predicted size for FpvR1–89–CBP,
which could be detected using antibodies against either
CBP or FpvR1–89 (Figure 1). Fractions that contained puri-
fied FpvR1–89–CBP also contained co-purified PvdS. PvdS
was not present in fractions obtained using the puri-
fication protocol with bacteria that did not contain the
FpvR1–89–TAP construct, confirming that purification of
PvdS was dependent on the presence of FpvR1–89–TAP.
FpvR1-89-CTAP










Figure 1 Co-purification of PvdS with FpvR1–89–TAP from P.
aeruginosa. Soluble protein was prepared from P. aeruginosa PAO1
fpvR expressing plasmid-borne (pUCP23) or chromosomally-
integrated (ctx) FpvR1–89 fused to a C-terminal TAP tag. Protein was
purified using the TAP protocol and the purified protein analyzed by
Western blotting for FpvR1–89-CBP or PvdS. (A) anti-CBP; (B) anti-FpvR;
(C) anti-PvdS. A mock purification was carried out with P. aeruginosa
PAO1 fpvR carrying pUCP23 without the fpvR1–89-TAP fusion as a
negative control for the TAP tag purification procedure. The positions
of molecular weight markers are shown.
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tion using a polyclonal FpvI antibody and a suitable
monoclonal antibody was not available.
The cytoplasmic region of FpvR inhibits sigma factor
activity in E. coli
To investigate the inhibition of FpvI and PvdS by FpvR1–89,
a system was established for detecting the activity of FpvI
or PvdS when co-expressed with FpvR1–89 in E. coli. The
pETDuet vector allows a 1:1 molar ratio of expression from
two multiple cloning sites (MCS). DNA encoding fpvR1–89
was inserted into MCS2 and either fpvI or pvdS was
inserted into MCS1, giving plasmids pETDuetfpvI_fpvR1–89and pETDuetpvdS_fpvR1–89 respectively (Table 1). Reporter
plasmids (Table 1) carrying fpvA or pvdE promoters fused
upstream of lacZ were used to detect FpvI or PvdS activity
respectively [6,30]. In the absence of FpvR1–89, FpvI in-
duced fpvA promoter activity and PvdS induced pvdE pro-
moter activity (Figure 2). The activity of FpvI and PvdS
was strongly repressed in the presence of FpvR1–89. These
results demonstrated the inhibitory function of the cyto-
plasmic region of FpvR on both FpvI and PvdS activity in
E. coli.
Co-purification of FpvR1–89 and FpvI or PvdS from E. coli
The pETDuet co-expression system was used to investigate
the interaction of FpvI and PvdS with FpvR1–89, via puri-
fication of hexahistidine-tagged FpvI or PvdS. FpvR1–89
co-purified with His6-FpvI and with His6-PvdS (Figure 3A
and B). FpvR1–89 was not purified when His6-FpvI or His6-
PvdS were absent (Additional file 1: Figure S2). In a recip-
rocal experiment, untagged FpvI and PvdS co-purified with
His6-FpvR1–67 that contains only the 67 N-terminal resi-
dues of FpvR (Additional file 1: Figure S3). These findings
demonstrated that the cytoplasmic region of FpvR forms
stable complexes with either FpvI or PvdS when co-
expressed in E. coli.
Identification of mutations that increase sigma factor
activity in the presence of FpvR1-89
The above data demonstrated binding and inhibition of
FpvI and PvdS by FpvR1–89. To further investigate interac-
tions of each sigma factor with FpvR1–89 we generated, se-
lected and characterized mutations that increased the
activity of FpvI and PvdS in the presence of FpvR1-89.
Error-prone PCR was used to introduce random muta-
tions into fpvI or pvdS and libraries of mutated genes were
cloned into MCS1 of pETDuet co-expressing fpvR1–89.
The mutagenesis method used minimizes bias in muta-
tions [40] and sequence analysis of 9 independent clones
(a total of 25 mutations) of mutagenized pvdS did not sug-
gest any mutational bias (Additional file 1: Table S2). The
resulting plasmid libraries were transformed into E. coli
containing either PfpvA::lacZ or PpvdE::lacZ, to screen for
gain-of-function mutations in fpvI and pvdS respectively.
Mutants exhibiting increased activity in the presence of
FpvR1–89 were identified on a qualitative basis as colonies
showing increased β-galactosidase activity on agar plates
supplemented with BCIG, as described in Methods.
Approximately 6% of FpvI mutant colonies and 0.5% of
PvdS mutant colonies had increased sigma factor activity
in this screen. Mutant fpvI and pvdS genes were sequenced
and their lacZ activities quantified. The properties of each
mutant confirmed to have increased sigma factor activity
are summarized in Additional file 1: Table S3 and S4. The
FpvI mutants contained one to five amino acid changes
with an average of two, and PvdS mutants contained one




PAO1 fpvR PAO1 with fpvR (PA2388) deletion [10]
PAO1 fpvR1–89-TAP PAO1 containing mini CTX2:: fpvR1–89-TAP This study
PAO1fpvR; pUCP23::fpvR1–89-TAP PAO1fpvR containing pUCP23::fpvR1–89-TAP; Gm
R, CbR This study
E. coli
S17-1 hsdR hsdM+ recA thi pro [integrated RP4-2-Tc::Mu, Km::Tn7]; SmR TpR [32]
JM83 F- ara Δ (lac-proAB) rpsL [Φ80, lacZΔM15] thi [33]
MC1061 ΔlacX74 Hsr− Hsm+ rpsL [34]
MC1061 (DE3) MC1061 lysogenized with λDE3 [lacI lacUV5-T7 gene 1] This study
Plasmids
pUCP23 lacIq lacZ(α-fragment) aacC1 ColE1 ori; RO1600 ori; Cb/AmpR, GmR [35]
pUCP23::fpvR1-89TAP 519 bp PCR fragment containing the fpvR promoter and 5′end of fpvR, joined to a C-terminal
TAP-tag and cloned into pUCP23
This study
Mini-CTX2 Self-proficient integration vector; TcR [36]
Mini-CTX2::fpvR1-89TAP 519 bp PCR fragment containing the fpvR promoter and 5′end of fpvR, joined to a C-terminal
TAP-tag and cloned into Mini-CTX2
This study
pFLP2 pRO1600 ori, sacB, flp recombinase; ApR/CbR [37]
pMP190::PfpvA_lacZ fpvA promoter cloned upstream of lacZ in pMP190; Cm
R [6]
pMP190::PpvdE_lacZ pvdE promoter cloned upstream of lacZ in pMP190; Cm
R [30,38]
pETDuet Dual expression vector; ApR [39]
pETDuet::fpvR1–89 fpvR1–89 cloned into MCS2 of pETDuet This study
pETDuet::fpvI fpvI cloned into MCS1 of pETDuet This study
pETDuet::pvdS pvdS cloned into MCS1 of pETDuet This study
pETDuet::fpvI_fpvR1–89 fpvI cloned into MCS1 and fpvR1–89 cloned into MCS2 of pETDuet This study













































































Figure 2 The activity of PvdS and FpvI in the presence and absence of FpvR1–89. β-galactosidase assays were carried out with E. coli
MC1061 (DE3) containing either (A) pMP190::PfpvA_lacZ or (B) pMP190::PpvdE_lacZ, along with pETDuet expressing FpvR1–89 and either (A) FpvI or
(B) PvdS. An empty pETDuet control is also shown to control for background expression of lacZ from pMP190::PfpvA_lacZ or pMP190::PpvdE_lacZ.
Averages were obtained from three biological replicates. Error bars are ±1 SD.
















































































Figure 3 Co-purification of FpvR1–89 with either His6-FpvI or His6-
PvdS from E. coli. Soluble protein was obtained from E. coli MC1061
(DE3) co-expressing either His6-FpvI and FpvR1-89 or His6-PvdS and
FpvR1–89. Protein was purified by nickel affinity chromatography via
the His6-tags on PvdS and FpvI and analyzed by SDS-PAGE (top panels)
and Western blotting (lower panels) using anti-FpvI, anti-PvdS or
anti-FpvR antibodies as shown. (A) Co-purification of FpvR1–89 with
His6-FpvI; (B) co-purification of FpvR1-89 with His6-PvdS. The positions
of molecular weight markers are shown.
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activities of the FpvI and PvdS mutants were generally sig-
nificantly higher than those of WT FpvI or PvdS (Figure 4;
Additional file 1: Table S3 and S4). One exception was mu-
tant PvdS S65G/Y136N/Q176* that had clearly increased
activity relative to WT PvdS on screening medium but not
in quantitative assays.
Many of the mutant genes contained multiple muta-
tions but all of the mutant genes contained at least one
mutation in or around conserved region four. Two sin-
gle mutations were engineered into fpvI and three into
pvdS by site-directed mutagenesis in order to investigate
the effects of the individual mutations on interactions of
the sigma factors with FpvR1–89. These mutations were
chosen because the corresponding amino acid residues
were altered in more than one mutant, they were located
in region four, or they apparently enhanced the activity
of a change in region four. Of these mutants, FpvIA145G and PvdS L165Q had higher activity than WT, al-
though the activity of the latter was not as high as in
F60V/L165Q or L64P/L165Q double mutants. PvdS F60V
alone showed no difference in activity from WT indicating
that F60V only had an effect on activity in the presence of
L165Q.
Activity of FpvI and PvdS mutants in the absence of
FpvR1–89
Increased activity of FpvI or PvdS mutants in the presence
of FpvR1–89 could be due to reduced affinity of the mutant
proteins for FpvR1–89 or to an intrinsic increase in sigma
factor activity, which could arise from several factors in-
cluding increased protein stability, improved affinity for
core RNA polymerase, or stronger promoter DNA bind-
ing. To distinguish between reduced affinity for FpvR1–89
and intrinsically increased activity of the sigma factors, five
FpvI and four PvdS mutants were compared with WT for
activity in the absence of FpvR1–89. The activities of the
FpvI mutants (Figure 5A) were not higher than WT FpvI;
indeed, for four of these mutants the activity was lower
than WT FpvI, which may indicate impaired function or
destabilized protein folding as a result of the mutations.
These data suggest that the increased activity of the FpvI
mutants in the presence of FpvR1–89 (Figure 4A) is be-
cause in each case the mutations reduce the ability of
FpvR1–89 to bind FpvI. In contrast, three of the PvdS mu-
tants had significantly higher activity than WT PvdS in
the absence of FpvR1–89 (Figure 5B). The increased activity
of these mutants in the presence of FpvR1–89 (Figure 4B)
may therefore be due at least in part to improved sigma
factor function or protein stability.
The mutations identified in FpvI cluster in region four
The identified mutations were mapped onto the con-
served regions of FpvI and PvdS [22]. The mutations
clustered in region four of FpvI (Figure 6), including sin-
gle mutations that increased the activity of FpvI in the
presence of FpvR1–89, suggesting that this region is im-
portant for binding of FpvI by FpvR. No obvious cluster-
ing of mutations was observed for PvdS, however the
sample size was small.
Investigating the effects of FpvI and PvdS C-terminal
deletions on activity
The truncation of PvdS by 12 amino acids due to the mu-
tation Q176* had no effect on activity in quantitative as-
says (Figure 4B). To further investigate the role of the
amino acids beyond region four in sigma factor activity,
five amino acids were removed from the C-terminal end of
FpvI (giving construct FpvI1–154) and 13 amino acids were
removed from the C-terminal end of PvdS (PvdS1–174)
(Figure 7A). FpvI1–154 had higher activity than WT FpvI in








































































































































































































Figure 4 The activity of FpvI and PvdS mutants in the presence of FpvR1–89. β-galactosidase assays were carried out with E. coli MC1061 (DE3)
containing (A) pMP190::PfpvA_lacZ or (B) pMP190::PpvdE_lacZ, along with pETDuet expressing FpvR1–89 and (A) mutant FpvI or (B) mutant PvdS. Dark
grey bars: FpvI and PvdS mutants generated by error prone PCR. Patterned bars: FpvI and PvdS mutants engineered by site directed mutagenesis. Light
grey bars: WT FpvI or PvdS. Mutants that were further investigated in Figure 5 are indicated in bold. Data were obtained from three biological replicates




































































































Figure 5 The activity of FpvI and PvdS mutants in the absence of FpvR1–89. β-galactosidase assays were carried out with E. coli MC1061
(DE3) containing (A) pMP190::PfpvA_lacZ or (B) pMP190::PpvdE_lacZ, along with pETDuet expressing (A) mutant FpvI or (B) mutant PvdS. Dark grey
bars: FpvI and PvdS mutants generated by error prone PCR. Patterned bars: FpvI and PvdS mutants engineered by site directed mutagenesis. Light
grey bars: WT FpvI or PvdS. Data were obtained from three biological replicates and error bars are ±1 SD. Statistically significant difference to WT
according to Student's T-test is indicated: *p <0.05, **p <0.01.
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Figure 6 The location of mutations in FpvI and PvdS that increased sigma factor activity in the presence of FpvR1–89. The approximate
location of mutations are shown on the ECF sigma factor functional regions two (2.1-2.4) and four (4.1 and 4.2) of (A) FpvI and (B) PvdS
according to the following classifications: ▲mutation(s) that gave higher activity in the presence, not absence of FpvR1–89; ■ mutation(s) that
gave higher activity whether or not FpvR1–89 was present; ● mutation(s) that gave higher activity in the presence of FpvR1–89 and were not




































































































Figure 7 The activity of FpvI and PvdS C-terminal deletion mutants. (A) An alignment of FpvI showing the 5 amino acid C-terminal deletion
and PvdS showing the 13 amino acid C-terminal deletion. (B and C) β-galactosidase assays were carried out with E. coli MC1061 (DE3) containing
pMP190::PfpvA_lacZ or pMP190::PpvdE_lacZ, along with pETDuet expressing FpvR1–89 and C-terminal deletion mutants of (B) FpvI or (C) PvdS. Values
are compared to WT FpvI and PvdS and were obtained from three biological replicates. Error bars are ±1 SD.
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the amino acids beyond the C-terminal of region four
are involved in binding to FpvR1–89. PvdS1–174 had higher
activity than WT in both the presence and absence
of FpvR1–89 (Figure 7C) suggesting that the removal of the
C-terminal 13 amino acids improved protein stability or
sigma factor function.
Discussion
Interactions between ECF sigma and anti-sigma factor
proteins have been experimentally demonstrated for a
small number of systems [23-27,41]. FpvR is unusual
amongst anti-sigma factors in that it inhibits the activities
of two different sigma factors, FpvI and PvdS [6,10]. Gen-
etic evidence has indicated that FpvR interacts directly
with both FpvI and PvdS [28]. Using the TAP-tag approach
we have now demonstrated that the cytoplasmic region of
FpvR does indeed bind to PvdS in P. aeruginosa, with
binding being stable enough to permit co-purification of
PvdS with the FpvR1–89-TAP construct. A key aspect of
the TAP-tag methodology is that proteins are expressed at
physiological levels, avoiding any artefacts that may result
from the use of overexpression constructs and providing
confidence that FpvR naturally binds PvdS. Binding of
FpvR1–89-TAP to PvdS in conjunction with extensive gen-
etic evidence for FpvR/FpvI interactions ([6,7,28], this
study) allow us to conclude that FpvR also binds to FpvI,
inhibiting its activity. However, we were unable to detect
co-purification of FpvI with FpvR1–89-TAP (data not
shown). This may be because the amount of FpvI in
P. aeruginosa, which has not been measured, is much
lower than the amount of PvdS (500–700 molecules per
cell [42,43]), or because FpvR1–89 has lower affinity for
FpvI than for PvdS, or due to limitations of the polyclonal
FpvI antibody.
Co-expression of FpvR1–89 with either PvdS or FpvI in
E. coli enabled purification of FpvR1-89–sigma factor
complexes, providing further evidence that the cytoplas-
mic region of FpvR can bind to both FpvI and PvdS. The
use of reporter gene constructs showed that binding
inhibited sigma factor activity. The pETDuet vector used
for these experiments gives approximately equal expres-
sion of co-expressed genes (in this case fpvR1–89 with ei-
ther fpvI or pvdS). The strong inhibition of sigma factor
activity seen in reporter gene assays (Figure 2), as well as
the approximately equi-molar amounts of FpvR1–89 and
FpvI/PvdS obtained following co-purification (Figure 3),
suggest that FpvR has a high affinity for each of its part-
ner sigma factor proteins despite their very different se-
quences. Comparisons of the small number of ECF
sigma factor structures available indicate that all have a
similar structure involving two alpha helix bundles, cor-
responding to regions two and four, connected by a
disordered region [23-26,41]. It is likely that FpvI andPvdS have the same overall structure with sigma factor-
specific features that are recognized by FpvR.
A bacterial 2-hybrid system was used previously to iden-
tify mutations that interfere with FpvR-sigma factor bind-
ing [28] although mutagenesis was not carried out on
PvdS and was only performed on the C-terminal section
of FpvI (FpvI95–159). A disadvantage of this system is that
loss of protein-protein interaction can occur through mu-
tations that have a non-specific effect on protein structure
or amount and indeed the majority of mutations identified
in that study resulted in reduced amounts of the mutant
protein. One amino acid change (L103P) was identified
that reduced affinity of FpvI for FpvR in the bacterial
2-hybrid system, while not affecting the amount of FpvI
protein. We reasoned that selection for gain-of-function
mutations using full-length FpvI and PvdS would identify
further residues involved in sigma-FpvR interactions,
while excluding mutations that caused reduced amounts
of sigma factor or disrupted the overall protein structure.
We therefore used the pETDuet co-expression system, in
conjunction with error-prone PCR and reporter gene as-
says, to identify gain-of-function mutations that increased
the activity of full length FpvI and PvdS in the presence of
FpvR1–89. A number of mutations (for example, FpvI
E139V/G; FpvI N132K/M153R; PvdS F133C/V and PvdS
L165Q) were obtained in independent screens, from dif-
ferent pools of mutagenized genes. This parallel evolution
suggests that these mutations were particularly effective
in increasing sigma factor activity in the presence of
FpvR1–89. Additional mutant genes containing single
mutations were engineered by site-directed mutagenesis.
Single mutations in FpvI (residues A102V, E139V/G,
R152P and A145G) increased the activity of FpvI in the
presence of FpvR1–89, implicating these residues in FpvR –
FpvI interactions. None of the mutant FpvI variants tested
had higher activity than WT in the absence of FpvR1–89
(Figure 5) showing that most if not all of the FpvI muta-
tions specifically affect interactions with FpvR.
Three of the four PvdS mutants tested had higher ac-
tivity than WT PvdS in the absence as well as the pres-
ence of FpvR1–89. This suggests that the effect of these
mutations was at least partially due to increased sigma
factor function or protein stability. In the absence of
FpvR, PvdS expressed in E. coli forms inclusion bodies
[44] and it may be that these mutations improve the
solubility of PvdS or alternatively its affinity for core
RNA polymerase or promoter DNA. PvdS L64P/L165Q
was the only PvdS mutant to show increased activity in
the presence of FpvR1–89 and similar activity to WT
PvdS in the absence of FpvR1-89, suggesting that this
combination of mutations disrupted interactions with
FpvR1–89.
Screening for increased activity of FpvI and PvdS in
the presence of FpvR1–89 gave different outcomes for the
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frequency (approximately 6% of colonies) and the mu-
tants tested had similar or lower activity than WT FpvI
in the absence of FpvR1–89. PvdS mutations were ob-
tained at a lower frequency (approximately 0.5% of col-
onies) and three of the four tested had higher activity
than WT PvdS in the absence of FpvR1–89. One explan-
ation for these differences is that mutations which dis-
rupt interactions of PvdS with FpvR1–89 also reduce the
activity of PvdS and so would not be identified in our
gain-of-function screen. Alternatively, interaction of FpvI
with FpvR1–89 may involve a relatively small number of
amino acid residue interactions and disrupting one of
these significantly reduces the affinity of FpvI for FpvR,
whereas PvdS-FpvR1–89 interactions may involve a larger
number of weaker interactions and disrupting only one
of these may not give a detectable reduction in inhib-
ition by FpvR1–89.
All the FpvI mutants that showed enhanced activity in
the presence of FpvR1–89 had mutations in or around re-
gion four (Figure 6). This provides clear evidence for the
role of this region in FpvR binding, consistent with earlier
findings [28]. The PvdS mutants that showed enhanced
activity in the presence of FpvR also had mutations in re-
gion four. However, fewer mutants were identified and the
majority of those tested had enhanced sigma factor func-
tion in the absence of FpvR1–89 making the role of region
four in binding to FpvR less clear-cut. Region four in each
of FpvI and PvdS is predicted to be involved in promoter
recognition at the −35 site [20,22,45] and structural data
for E. coli housekeeping sigma 70 shows all regions of
sigma 70 to make contact with core RNA polymerase [45].
Therefore, FpvR binding to region four might sterically
interfere with both promoter recognition and recruitment
of core RNA polymerase. There is considerable variability
amongst ECF sigma factors in the region bound by the
cognate anti-sigma factor which can be both region two
and four [23-25], region two alone [26] or region four
alone [27]. FpvR binding and sequestering any of these re-
gions would likely disrupt recruitment of core RNA
polymerase.
Although region four of FpvI is clearly critical for inter-
actions with FpvR1–89, our results also suggest some in-
volvement of region two in either improving sigma factor
function or in interactions with FpvR1–89. For example,
changes at residue S37 in region 2.2 of FpvI arose in three
separate screens in combination with additional mutations.
The PvdS double mutants F60V/L165Q and L64P/L165Q
showed markedly higher activity than the PvdS L165Q
mutant in the presence of FpvR1–89. For PvdS F60V/
L165Q the effect appeared to be synergistic because the in-
dividual mutants showed no difference in activity to WT
PvdS. These results, together with the fact that no im-
proved mutants were identified containing only a mutationin region two, suggest that changes in region two stabilized
the protein or improved sigma factor function.
One mutation identified in our initial screen was PvdS
Q176*, although this mutation did not increase activity
of PvdS in quantitative assays. This suggested that the
12 amino acids at the C-terminus of PvdS, which occur
after region four, are not required for sigma factor func-
tion. An engineered mutant where the last 13 amino
acids of PvdS were deleted showed higher activity than
WT while apparently retaining interaction with FpvR1–
89. It is possible that the residues at the C-terminal end
of region four act as a signal targeting PvdS for degrad-
ation [46]. Removal of these residues could improve sta-
bility of the protein. Alternatively it could enhance
interactions with core RNA polymerase if the flexibility
of these residues decreases the strength of interaction.
Deletion of five residues at the C-terminal of FpvI re-
sulted in increased sigma factor activity in the presence
of FpvR1–89 suggesting that this region also contributes
to binding by FpvR1–89.
Conclusions
The cytoplasmic domain of FpvR forms stable interac-
tions with PvdS in both P. aeruginosa and E. coli, and
with FpvI in E. coli, despite the relatively low sequence
identity of the sigma factors. Region four of FpvI as well
as the C-terminus of this protein are of primary import-
ance in binding to FpvR and we have identified four
amino acid residues in FpvI that are likely to play a key
role in its interaction with FpvR. It is likely that FpvI
and PvdS share the same general tertiary structure that,
in combination with specific residue interactions, is rec-
ognized by FpvR although we were unable to identify
any single mutations that clearly reduced the affinity of
PvdS for FpvR1–89. Our data are consistent with a model
whereby FpvR inhibits FpvI and PvdS by occluding their
binding to core RNA polymerase.
Methods
General methods
Bacterial strains used in this study are listed in Table 1.
Bacteria were routinely grown in LB medium or on LB
agar at 37°C. P. aeruginosa was grown using King’s B
medium [47] for preparation of protein extracts. Media
were supplemented with ampicillin (50 μg · mL−1), chlor-
amphenicol (30 μg · mL−1), carbenicillin (300 μg · mL−1),
tetracycline (25 μg · mL−1) or gentamicin (300 μg · mL−1)
as required. E. coli MC1061 (DE3) was derived by lysog-
enizing E. coli MC1061 with λDE3 prophage (Novagen)
using the manufacturer’s protocol.
Genetic manipulations
DNA constructs were made using PCR, with the PCR
primers (Additional file 1: Table S1) containing introduced
Edgar et al. BMC Microbiology 2014, 14:287 Page 10 of 12
http://www.biomedcentral.com/1471-2180/14/287restriction sites to enable cloning. A PCR fragment com-
prising the fpvR promoter and the 5′ end of fpvR, encod-
ing the predicted cytoplasmic part of FpvR (residues 1–89;
designated fpvR1–89) was amplified from P. aeruginosa
PAO1 genomic DNA using primers miniPfpvRXbaIfor
and fpvRNEcorRIrev. This fragment was ligated (via the
introduced EcoRI site) to an EcoRI-digested fragment en-
coding a C-terminal TAP tag (C-TAP) that had been amp-
lified with primers CTAPEcoRIfor and CTAPBamHIrev
from plasmid pCTAPi [48]. The resulting fpvR1–89-TAP
fragment was cloned into pUCP23 [35] and miniCTX2
[36] using the introduced XbaI and BamHI restriction
sites. Plasmids were introduced into P. aeruginosa by
transformation or by conjugation from E. coli S17-1, and
miniCTX2 vector sequences were then excised from the
integrated miniCTX2 construct, as described previously
[36]. pETDuet constructs were made by amplifying fpvR1–
89, pvdS and fpvI from P. aeruginosa PAO1 genomic DNA
using appropriate primers (Additional file 1: Table S1) and
then cloning the resulting PCR fragments into pETDuet-1
[39]. The fidelity of all constructs was verified by DNA
sequencing.
Protein purification
Proteins were purified from P. aeruginosa using the tan-
dem affinity tag (TAP tag) method [29], with all purifica-
tion steps carried out at 4°C. Following 24 h incubation at
37°C, bacteria were collected from 1.2 L of culture by cen-
trifugation (6160 × g, 15 min), resuspended in chilled lysis
buffer (10 mM Tris-Cl [pH 8.0], 75 mM NaCl, 0.05% (v/v)
Tween 20, 20% (v/v) glycerol, 25 mM KCl, 2 mM EDTA
[pH 8.0], 0.5 mM DTT, 0.5 mM PMSF) (10 mL) and lysed
by sonication (Sonics Vibra Cell). The lysed cells were cen-
trifuged (16,000 × g, 30 min) and the supernatant was ap-
plied to an IgG sepharose column (Amersham Biosciences/
GE Healthcare) (0.5 mL) that had been equilibrated with
lysis buffer. The column was washed with approximately
20 volumes of lysis buffer then equilibrated with AcTEV
cleavage buffer (Invitrogen). The column-bound protein
was treated with 100 U of AcTEV protease (Invitrogen)
(12 h). The released protein was collected, mixed with an
equal volume (1 mL) of calmodulin binding buffer (10 mM
Tris-Cl [pH 8.0], 75 mM NaCl, 2 mM CaCl2, 0.05% (v/v)
Tween 20, 10 mM β-mercaptoethanol, 0.5 mM PMSF)
containing Complete™ protease inhibitor Mini tablet
(Roche) (1 tablet/100 ml of buffer). It was then applied to
a calmodulin sepharose column (Amersham Biosciences/
GE Healthcare), washed twice with calmodulin binding
buffer and then washed using fresh calmodulin binding
buffer in which the concentration of Tween 20 had been
amended to 0.02% (w/v). Elution buffer (10 mM Tris-Cl
[pH 8.0], 100 mM NH4HCO3, 10 mM EGTA, 10 mM β-
mercaptoethanol) (1.2 mL applied in 6 aliquots) was then
added and the protein collected.Proteins expressed as hexahistidine fusions in pET-
Duet were purified from E. coli by nickel-affinity chro-
matography. Cultures grown for 16 h were used to
inoculate fresh media to OD600 = 0.1. Expression was in-
duced at OD600 = 0.6 using a final IPTG concentration
of 14 μg · mL−1 at 18°C for 16 h. The cells were collected
by centrifugation and then resuspended in binding buf-
fer (50 mM sodium phosphate [pH 8.0], 300 mM NaCl).
Cell lysis was carried out using sonication as described
above. The soluble fractions were obtained by centrifu-
gation and applied to nickel-affinity chromatography
resin (BioRad) equilibrated in binding buffer. The resin
was washed four times in wash buffer (50 mM sodium
phosphate [pH 8.0], 300 mM NaCl, 30 mM imidazole)
prior to elution in elution buffer (50 mM sodium phos-
phate [pH 8.0], 300 mM NaCl, 250 mM imidazole).
Proteins were analyzed by SDS-PAGE and Western
blotting as described previously [14,43] using monoclo-
nal antibodies against CBP (Upstate, Millipore), PvdS
[49], the N-terminal (cytoplasmic) portion of FpvR [14],
and a polyclonal antibody against FpvI (generated in-
house), applied to the membrane sequentially.
β-galactosidase reporter gene assays
Bacteria were inoculated in duplicate into 150 μL over-
night cultures in LB amended with appropriate antibi-
otics and 0.4% glucose in wells of a 96-well flat bottom
microtiter plate and grown for 16 h, 200 rpm at 37°C.
Wells of a fresh microtiter plate, each containing 200 μL
LB, antibiotics and 0.2% glucose, were inoculated with
15 μL of the overnight culture and incubated for 4 h,
200 rpm at 30°C. Portions (100 μL) of the resulting
micro-cultures were inoculated into wells of a microtiter
plate containing induction media (100 μL LB, antibiotics,
0.05 mM IPTG, 0.2% glucose) and incubated for 1 h,
200 rpm at 30°C. Absorbance was measured at OD600
using an Enspire plate reader (Perkin Elmer). For the
assay, 20 μL of each induced culture were added to so-
dium phosphate buffer (84 μL, 40 mM, pH 7.0) contain-
ing ZOB buffer (46 μL) [50] and immediately incubated
in the plate reader at 37°C without shaking. Absorbance
readings at OD420 were taken at time zero and then
every 2 minutes for 30 minutes. Absorbance readings for
LB control wells were subtracted from the data. The en-
zyme activity for each well was calculated using the
Miller equation [51]. Each assay was carried out in
triplicate.
Mutagenic PCR
A mutagenic PCR protocol was developed using Red
Hot Taq polymerase (ABgene) that lacks 3′-5′ exo-
nuclease activity, and error prone buffer conditions
based on those described in [40]. The error prone PCR
protocol used has been shown to minimize the intrinsic
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currence of mutation hotspots. Each reaction contained
2 μL 10 × mutagenic PCR buffer (70 mM MgCl2, 500 mM
KCl, 100 mM Tris–HCl, [pH 8.2]), 2 μL 10 × dNTP
(2 mM dGTP, 2 mM dATP, 15 mM dCTP, 10 mM dTTP),
1 μL 6 pmol · μL−1 forward primer, 1 μL 6 pmol · μL−1 re-
verse primer, 11 μL ddH2O, 2 μL 5 mM MnCl2, 0.4 μL
Red Hot Taq polymerase, and 0.6 μL 5 ng · μL−1 template
DNA. The reactions were incubated for 4 minutes at 94°C,
followed by 30 cycles of 30 seconds at 94°C, 30 seconds at
55°C and 2 minutes at 72°C. For mutagenesis of pvdS, mu-
tagenic PCR was carried out using primers pvdSBamHIfor
and pvdSSalIrev (Additional file 1: Table S1), with pET-
Duet::pvdS as template. For mutagenesis of fpvI, muta-
genic PCR was carried out using primers fpvIBamHIfor
and fpvISacIstoprev (Additional file 1: Table S1) with pET-
Duet::fpvI as template. Libraries of mutated PCR products
were cloned into pGEM-T Easy (Promega) and then
sub-cloned into pETDuet_fpvR1–89 for screening. Three
separate pvdS and fpvI libraries were made. Libraries were
grown on LB agar containing 24 μg · mL−1 IPTG and
120 μg · mL−1 BCIG. Mutants that had enhanced re-
porter plasmid activity were identified as deeper blue
colonies and were analyzed by DNA sequencing and β-
galactosidase assay.
Overlap PCR was used to generate single mutations in
fpvI and pvdS genes. The genes were amplified from
PAO1 genomic DNA using Phusion High-Fidelity poly-
merase (Thermo Scientific) in two fragments using
primers (Additional file 1: Table S1) that created a 25 bp
overlap. Overlap PCR was performed using Biomix Red
master mix (Bioline) with the two purified template frag-
ments at equi-molar concentration totaling 100 ng in a
volume of 40 μL. The reactions were initially incubated in
the absence of primers for 2 minutes at 95°C, followed
by 15 cycles of 30 seconds at 95°C, 30 seconds at 55°C,
30 seconds/kb at 72°C. The full length primers were
then added in 20 μL of Biomix Red, adjusted for the
final reaction volume of 60 μL. The reactions were in-
cubated for an additional 15 cycles of 30 seconds at 95°C,
30 seconds at 67°C, 30 seconds/kb at 72°C, followed by
5 minutes at 72°C.
Additional file
Additional file 1: Supplemental tables S1-S4 and figures S1-S3
associated with this manuscript.
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